J
John T. Wei
Researcher at University of Michigan
Publications - 395
Citations - 32685
John T. Wei is an academic researcher from University of Michigan. The author has contributed to research in topics: Prostate cancer & Cancer. The author has an hindex of 82, co-authored 385 publications receiving 30140 citations. Previous affiliations of John T. Wei include Johns Hopkins University & United States Department of Veterans Affairs.
Papers
More filters
Journal ArticleDOI
Quality of life and satisfaction with outcome among prostate-cancer survivors.
Martin G. Sanda,Rodney L. Dunn,Jeff M. Michalski,Howard M. Sandler,Laurel L. Northouse,Larry Hembroff,Xihong Lin,Thomas K. Greenfield,Mark S. Litwin,Mark S. Litwin,Christopher S. Saigal,Arul Mahadevan,Eric A. Klein,Adam S. Kibel,Louis L. Pisters,Deborah A. Kuban,Irving D. Kaplan,Darien Wood,Jay P. Ciezki,Nikhil L. Shah,John T. Wei +20 more
TL;DR: Each prostate-cancer treatment was associated with a distinct pattern of change in quality-of-life domains related to urinary, sexual, bowel, and hormonal function, and these changes influenced satisfaction with treatment outcomes among patients and their spouses or partners.
Journal ArticleDOI
Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression
Arun Sreekumar,Laila M. Poisson,Thekkelnaycke M. Rajendiran,Amjad Khan,Qi Cao,Jindan Yu,Bharathi Laxman,Rohit Mehra,Robert J. Lonigro,Yong Li,Mukesh K. Nyati,Aarif Ahsan,Shanker Kalyana-Sundaram,Bo Han,Xuhong Cao,Jaeman Byun,Gilbert S. Omenn,Debashis Ghosh,Subramaniam Pennathur,Danny C. Alexander,Alvin Berger,Jeffrey R. Shuster,John T. Wei,Sooryanarayana Varambally,Christopher A. Beecher,Arul M. Chinnaiyan +25 more
TL;DR: Sarcosine, an N-methyl derivative of the amino acid glycine, was identified as a differential metabolite that was highly increased during prostate cancer progression to metastasis and can be detected non-invasively in urine.
Journal ArticleDOI
Radical prostatectomy versus observation for localized prostate cancer.
Timothy J Wilt,Michael K. Brawer,Karen M. Jones,Michael J. Barry,William J. Aronson,Steven Fox,Jeffrey R. Gingrich,John T. Wei,Patricia Gilhooly,B. Mayer Grob,Imad Nsouli,Padmini Iyer,Ruben Cartagena,Glenn Snider,Claus G. Roehrborn,Roohollah Sharifi,William Blank,Parikshit Pandya,Gerald L. Andriole,Daniel J. Culkin,Thomas M. Wheeler +20 more
TL;DR: Among men with localized prostate cancer detected during the early era of PSA testing, radical prostatectomy did not significantly reduce all-cause or prostate-cancer mortality, as compared with observation, through at least 12 years of follow-up.
Journal ArticleDOI
Development and validation of the expanded prostate cancer index composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer.
TL;DR: EPIC is a robust prostate cancer HRQOL instrument that complements prior instruments by measuring a broad spectrum of urinary, bowel, sexual, and hormonal symptoms, thereby providing a unique tool for comprehensive assessment ofHRQOL issues important in contemporary prostate cancer management.
Journal ArticleDOI
Transcriptome sequencing across a prostate cancer cohort identifies PCAT-1 , an unannotated lincRNA implicated in disease progression
John R. Prensner,Matthew K. Iyer,O. Alejandro Balbin,Saravana M. Dhanasekaran,Qi Cao,J. Chad Brenner,Bharathi Laxman,Irfan A. Asangani,Catherine S. Grasso,Hal D. Kominsky,Xuhong Cao,Xiaojun Jing,Xiaoju Wang,Javed Siddiqui,John T. Wei,Dan R. Robinson,Hari Iyer,Nallasivam Palanisamy,Christopher G. Maher,Arul M. Chinnaiyan +19 more
TL;DR: The utility of RNA-Seq to identify disease-associated ncRNAs that may improve the stratification of cancer subtypes is established and it is suggested that PCAT-1 is a transcriptional repressor implicated in a subset of prostate cancer patients.